AI Agents: From Automation to Augmented Intelligence
Justyna Lisowska July 9, 2026
TIDES 2026: Oligonucleotide Discovery is Moving to ‘The Beach’
Ming Wang July 7, 2026
Adventitious Viral Detection in Biologics Manufacturing
Alison Waterfield July 7, 2026
Bristol Myers Squibb
Implementing NGS‑Based Assays in GxP Environments
Valentina Armiento July 7, 2026
Enabling NGS for Product Characterization and Biosafety in GxP
Designing Next-Gen Bioprocesses
Why AI Alone Will Not Solve Oligonucleotide Discovery
Justyna Lisowska, Ming Wang July 2, 2026
Driving Biopharma Automation and AI
Merck: Digitally Transforming Drug Discovery with Automated Data Workflows
NGS-Powered Quality Control: A New Standard for Biopharma
Arielle Mann June 16, 2026
NGS in GMP Manufacturing: Reducing Risk, Increasing Return
Christoph Bredack June 15, 2026
Unified Platform for Automated Developability Assessment and AI-Driven Predictive Modeling
Leveraging Genedata Screener for Biophysical Developability Assessment in Discovery Biologics Screening
Mass Spec Data Digital Transformation at Lilly Biologics Discovery
How Challenges in Biologics Development Catalyze Innovations in Cell Line Development
Unified Platform for E2E Bioprocess Optimization
Cyclic Peptide Characterization with Custom Unnatural Amino Acids
Genedata Biologics Sample Management Solution
Japan: Thinking Plasma Biomarkers for Alzheimer’s Disease End-to-End
NGS for Automated & Regulatory-Compliant Monitoring of CQAs in Biologics
AI-Driven & GMP-Compliant Digital Infrastructure for NGS-Based Assays
Modernizing Biopharma QC with GxP-Compliant NGS In-House
Novartis Accelerates IND Timelines by Digitalizing CMC Processes
Enhanced Affinity Selection–Driven Hit Filtering
Fully Automated mRNA Mapping for MS/MS-Based Product QA Analysis
Consistency and Data Quality in Protein Mapping Through Rule-Based Automation
Morphological Clustering for AI-based Quality Control of LC–MS
Evaluation of Disulfide Bond Scrambling in mAb peptide Mapping
Integrated HRPF Workflows for Structural MS Data Processing
Middle‑Down MS for Disulfide Mapping in Multispecific Proteins
Industry Perspectives on Preparing Validation-Ready NGS Workflows
Alison Waterfield May 17, 2026
Digitalizing CMC Processes at Novartis
Next Era of Bioprocessing: Driving Innovation through Digital CMC and AI
Unlocking NGS and Regulatory Synergy in GCT for Maximum Impact
NGS for Product Characterization in CGT: Biosafety and Genome Integrity
From Science to Compliance: Effective Validation of Genedata Selector
Genedata for Developability Across Biopharma R&D
Discover What’s New in Genedata Screener 2026
Genedata Biopharma Platform: Compliance-Ready
Screen Smarter: Automating Oligonucleotide Hit Selection
